Biodexa Pharmaceuticals Shares Set to Reverse Split on Monday, October 26th (NASDAQ:BDRX)

Shares of Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) are scheduled to reverse split on the morning of Monday, October 26th. The 1-8 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Sunday, October 25th.

Biodexa Pharmaceuticals Price Performance

Biodexa Pharmaceuticals stock opened at $0.35 on Wednesday. The company’s 50-day moving average price is $0.95 and its two-hundred day moving average price is $2.30. Biodexa Pharmaceuticals has a 52 week low of $0.34 and a 52 week high of $44.70.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut shares of Biodexa Pharmaceuticals from a “sell (e+)” rating to a “sell (e)” rating in a report on Monday, September 28th. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat, Biodexa Pharmaceuticals presently has an average rating of “Sell”.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Biodexa Pharmaceuticals stock. Sabby Management LLC purchased a new stake in Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 190,658 shares of the company’s stock, valued at approximately $433,000. Biodexa Pharmaceuticals comprises approximately 0.6% of Sabby Management LLC’s portfolio, making the stock its 10th biggest position. Sabby Management LLC owned 28.04% of Biodexa Pharmaceuticals as of its most recent filing with the SEC. 17.51% of the stock is owned by institutional investors and hedge funds.

Biodexa Pharmaceuticals Company Profile

Biodexa Pharmaceuticals plc, formerly known as Midatech Pharma plc, is a biopharmaceutical company focused on developing medicines for diseases with significant unmet medical needs. The company’s work has centered on oncology, rare diseases and conditions that are difficult to treat with conventional drug-delivery methods.

Biodexa’s development programs have included MTX110, a proprietary aqueous formulation of panobinostat being investigated for direct administration into brain tumors, including diffuse intrinsic pontine glioma.